相关临床试验
312
12 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1889
进行中（未招募）
9
2.9%
已完成
179
57.4%
Enrolling By Invitation
1
0.3%
尚未招募
2
0.6%
招募中
29
9.3%
终止
52
16.7%
撤回
40
12.8%
暂无批准数据
- University of New Mexico researchers found microplastic concentrations in brain tissue 7 to 30 times higher than in liver or kidney samples from the same bodies. - Brain plastic levels rose approximately 50% between 2016 and 2024, with 2024 samples containing a median of roughly 4,800 micrograms per gram of tissue. - Dementia patients showed notably higher plastic concentrations, though researchers caution the disease may impair clearance mechanisms rather than plastics causing dementia. - The study's modest sample size of 52 brain specimens and only two time points represent key limitations; no causal link between plastics and health impacts has been established.
- A first-of-its-kind fluorescent drug called bevonescein successfully highlighted nerve tissue during surgery in a Phase 1-2 trial involving 27 cancer patients undergoing head and neck procedures. - The drug binds selectively to nerve tissue and emits a greenish-yellow glow under special lighting, allowing surgeons to better identify and avoid critical nerves during operations. - A larger Phase 3 trial is currently underway across 10 sites to determine if the imaging agent meaningfully improves overall surgical outcomes, with completion expected by summer. - If successful, bevonescein could receive FDA approval for head and neck surgeries and potentially expand to off-label use in other surgical procedures throughout the body.
- University of New Mexico researchers have developed a vaccine that generates antibodies against pathological tau protein (pT181), showing efficacy in both mice and non-human primates with strong immune responses. - The vaccine uses virus-like particles (VLPs) as a delivery platform, requiring only one primary shot and two boosters without adjuvants, demonstrating safety and durability in preclinical studies. - Researchers are now seeking funding to advance to Phase 1 human clinical trials, potentially offering a more effective approach than current amyloid beta-targeting treatments that show only modest effects on Alzheimer's progression.
- A clinical trial found that hospital-based addiction consultation services more than doubled the rate of medication initiation for opioid use disorder during hospitalization (57.3% vs 26.7% with usual care). - The Substance Use Treatment and Recovery Team (START) intervention significantly improved post-discharge treatment linkage, with 72% of intervention patients accessing follow-up care compared to 48.1% in the usual care group. - Researchers suggest the model could address critical gaps in OUD treatment by leveraging hospitalization as an opportunity to overcome barriers like stigma, housing instability, and healthcare access issues.
